Back to compounds

COMPOUND PROFILE / SMALL MOLECULES

Danuglipron.

Research draft

Danuglipron is an oral small-molecule GLP-1 receptor agonist formerly developed for metabolic disease.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Danuglipron is an oral small-molecule GLP-1 receptor agonist formerly developed for metabolic disease.

CLASSIFICATIONSmall molecules
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It activates GLP-1 receptors without a peptide structure.

Human research

Randomised diabetes and obesity studies showed metabolic activity, with substantial tolerability-related discontinuation in development.

Preclinical & other research

Laboratory work characterised oral receptor activity.

Safety & unknowns

Gastrointestinal burden and a development liver-safety concern are material limitations.

Regulatory status

Pfizer announced discontinuation of development; a promising trial result does not establish approval.

Reported use & evidence

Research profile draft

The supplied Danuglipron profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds